Jiménez-Jiménez F J, Molina J A, Aguilar M V, Jorge-Santamaría A, Mateos-Vega C J, González-Muñoz M J, Cabrera-Valdivia F, Ayuso-Peralta L, Benito J, Vázquez A
Department of Neurology, Hospital Universitario, Príncipe de Asturias, Madrid, Spain.
Acta Neurol Scand. 1995 Nov;92(5):369-71. doi: 10.1111/j.1600-0404.1995.tb00148.x.
Some investigators reported pharmacogenetic differences in the metabolism of sulfur-containing drugs and lower plasma sulfate levels in patients with Parkinson's disease (PD) compared with controls. However, other group did not confirm these findings. We studied the plasma levels of sulfate by indirect atomic absorption spectrophotometry in 55 PD patients and 57 age and sex-matched controls. The plasma sulfate levels did not differ significantly between PD patients and control groups (mean +/- SEM 73 +/- 8 and 75 +/- 7 mg/l, respectively). They were not influenced by antiparkinsonian drugs and they did not correlate with age at onset, duration, Hoehn & Yahr staging or activities of daily living subscale of the Unified Parkinson's disease rating scale. There was a low but significant correlation of plasma sulfate levels with motor examination (r = -0.39, p < 0.05) and total score (r = -0.33, p < 0.05) of this scale in the PD group. These data suggest that plasma sulfate levels are apparently unrelated with the risk for PD.
一些研究人员报告称，与对照组相比，帕金森病（PD）患者体内含硫药物的代谢存在药物遗传学差异，且血浆硫酸盐水平较低。然而，其他研究团队并未证实这些发现。我们采用间接原子吸收分光光度法研究了55例PD患者以及57例年龄和性别匹配的对照者的血浆硫酸盐水平。PD患者组和对照组之间的血浆硫酸盐水平无显著差异（分别为均值±标准误73±8和75±7mg/L）。它们不受抗帕金森病药物的影响，且与发病年龄、病程、Hoehn & Yahr分期或统一帕金森病评定量表的日常生活能力分量表无关。在PD组中，血浆硫酸盐水平与该量表的运动检查（r = -0.39，p < 0.05）和总分（r = -0.33，p < 0.05）存在低但显著的相关性。这些数据表明，血浆硫酸盐水平显然与患PD的风险无关。
